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Abstract
Background: The phosphoinositide 3-kinase (PI3K)/Akt pathway plays a fundamental role in cell proliferation and
survival in human tumorigenesis, including gastric cancer. PIK3CA mutations and amplification are two major causes
of overactivation of this pathway in human cancers. However, until this work, there was no sound investigation on
the association of PIK3CA mutations and amplification with clinical outcome in gastric cancer, particularly the latter.
Methods: Using direct sequencing and real-time quantitative PCR, we examined PIK3CA mutations and
amplification, and their association with clinicopathological characteristics and clinical outcome of gastric cancer
patients.
Results: PIK3CA mutations and amplification were found in 8/113 (7.1%) and 88/131 (67%) gastric cancer patients,
respectively. PIK3CA amplification was closely associated with increased phosphorylated Akt (p-Akt) level. No
relationship was found between PIK3CA mutations and clinicopathological characteristics and clinical outcome in
gastric cancer. PIK3CA amplification was significantly positively associated with cancer-related death. Importantly,
Kaplan-Meier survival curves revealed that the patients with PIK3CA amplification had significantly shorter survival
times than the patients without PIK3CA amplification.
Conclusions: Our data showed that PIK3CA mutations were not common, but its amplification was very common
in gastric cancer and may be a major mechanism in activating the PI3K/Akt pathway in gastric cancer. Importantly,
Kaplan-Meier survival curves revealed that PIK3CA amplification was significantly positively associated with poor
survival of gastric cancer patients. Collectively, the PI3K/Akt signaling pathway may be an effective therapeutic
target in gastric cancer.
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Background
G a s t r i cc a n c e ri sh i g h l yp r e v a lent in Asia, particularly
China, and is one of the leading cause of cancer-related
death worldwide [1]. The histological classifications of
gastric cancer involve two distinct types, intestinal and
diffuse [2]. Although recent diagnostic and therapeutic
advances have provided excellent survival for patients
with early gastric cancer, the gastric cancer is usually
diagnosed at an advanced stage and the prognosis is still
poor [3], reflecting limited advances in our understanding
of the pathogenesis of this disease and the molecular
events that contributed to its development. A better
understanding of the molecular mechanisms of gastric
cancer may lead to new diagnostic, therapeutic and pre-
ventive approaches to this disease.
Gastric cancer is chronic proliferative disease charac-
terized by multiple genetic and epigenetic events [4-6].
The aberrant signaling of major pathways is involved in
this process, including phosphoinositide 3-kinase
(PI3K)/Akt pathway, which plays a fundamental role in
cell proliferation and survival in gastric tumorigenesis
[7-9]. A key step in the signaling of PI3K/Akt pathway
is the generation of phosphatidylinositol-3,4,5-trispho-
sphate (PIP3) catalyzed by PI3K. PI3K is composed of
heterodimers of a p85 regulatory subunit and one of the
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of the catalytic subunits, only the a-type, PIK3CA, has
been shown to harbor oncogenic mutations in human
cancer [10-12], including gastric cancer [13-15], imply-
ing an important role of PIK3CA mutations in gastric
carcinogenesis. In addition to mutations, genomic
amplification of PIK3CA has been reported in various
human cancers, including ovarian cancer, cervical can-
cer, thyroid cancer, and non-small cell lung cancer
(NSCLC) [16-19]. Increased copy number of PIK3CA
was closely associated with elevated mRNA or protein
expression [16-18]. Importantly, PIK3CA overexpression
caused by gene amplification increased PI3-kinase activ-
ity and phosphorylated Akt level, which was associated
with aberrant cell proliferation and apoptosis, both of
which are directly linked to tumorigenesis [16,17,20].
In the present study, we analyzed a large cohort of clini-
cally well-characterized gastric cancers for the presence of
mutations in the exons 9 and 20 of PIK3CA gene by direct
sequencing and PIK3CA amplification by real-time quanti-
tative PCR, and correlated the presence of PIK3CA muta-
tions and amplification with clinicopathological
characteristics and clinical outcome of gastric cancer
patients.
Methods
Clinical samples
With the institutional review board approval, a total of
131 paraffin-embedded gastric cancer tissues were ran-
domly obtained from the First Affiliated Hospital of Xi’an
Jiaotong University School of Medicine. The 37 normal
controls from the patients with chronic gastritis who
underwent endoscopic biopsy, were also obtained from
the First Affiliated Hospital of Xi’an Jiaotong University
School of Medicine. None of these patients received che-
motherapy and radiotherapy before the surgery. Informed
consent was obtained from each patient before the sur-
gery. All of the samples were histologically examined by a
pathologist at Department of Pathology of the Hospital to
identify the clinicopathologic characteristics of the
tumors, which are shown in Table 1.
Tissues and DNA preparation
Serial sections from each tumor sample were cut. One
section (5 μm) was stained by hematoxylin and eosin
(H&E) and a tumor representative tissue was marked by
an expert surgical pathologist for gastric cancer. The
next section (8 μm) was deparaffinized and stained with
hematoxylin. Tumor tissues were isolated by manual
microdissection under an inverted microscope using the
marked H&E section for target tissue identification.
Genomic DNA was extracted from isolated tissues as
previously described [18]. Briefly, after a treatment for
overnight at room temperature with xylene to remove
pareffin, tissues were digested with 1% sodium dodecyl
sulfate (SDS) and 0.5 mg/ml proteinase K at 48°C for
48 h, with addition of several spiking aliquots of concen-
trated proteinase K to faciliate digestion. DNA was sub-
sequently isolated using standard phenol/chloroform
protocol, and was dissolved in distilled water and stored
at -80°C until use. Subsequent tissue sections (5 μm)
were prepared on 3-aminopropyltriethoxysilane (APTES)
coated slides for immunohistochemical assay.
Mutation analysis of PIK3CA gene
In the present study, we selected exon 9 (for the regula-
tory helical domain) and exon 20 (for the kinase domain)
of PIK3CA gene, two mutational hotspot regions, for
mutation analysis as previous large-sclae analysis of
PIK3CA mutations in various human cancers revealed
that > 80% of the mutations clustered within these
domains [10,13,21,22]. Genomic DNA was amplified by
PCR using the amplifying and sequencing primers for
these exons of PIK3CA gene as described previously [10].
The PCR was performed in a final volume of 20 μlo na
96-well plate, which containing~60 ng genomic DNA,
16.6 mM ammonium sulfate, 67 mM Tris (pH 8.8), 5%
dimethylsulfoxide, 2 mM MgCl2, 10 mM 2-mercap-
toethanol, 200 μM of each deoxynucleotide triphosphate
(dATP, dCTP, dGTP, and dTTP), 200 nM of each primer
( f o r w a r da n dr e v e r s e ) ,a n d0 . 6Up l a t i n u mD N ATaq
polymerase (Invitrogen Life Technologies, Inc., Gaithers-
burg, MD). Step-down PCR was run in a Thermal cycler
(Bio-Rad Laboratories, Inc., CA) as follows: after a 4-min
denaturing at 95°C, the PCR was run with each tempera-
ture for 1 min at six step-down steps, for two cycles each.
The denaturing temperature was 95°C, and extension
temperature was 72°C for each step, with the annealing
temperature of 66°C, 64°C, 62°C, 60°C, 58°C, and 56°C
from the first to the last step. The PCR was finally run at
95°C, 56°C, and 72°C each for 1 min for 35 cycles, fol-
lowed by an elongation at 72°C for 5 min. The PCR pro-
ducts were electrophoresed on a 1.2% agarose gel and
visualized under UV illumination using an ethidium bro-
mide stain. The direct sequencing was performed to ana-
lyze PIK3CA mutations on an ABI PRISM 3700 DNA
Analyzer (Applied Biosystems) at the sequencing core of
Beijing Genomics Institute (BGI, Beijing).
Copy number analysis of PIK3CA gene with real-time
quantitative PCR
We analyzed the copy number of PIK3CA gene in 131
gastric cancer samples and 37 controls by real-time
quantitative PCR technique on a CFX384 Thermal Cycler
Dice™ real-time PCR system (Bio-Rad Laboratories, Inc.,
CA) as described previously [23]. This method was well
established and validated by florescence in situ hybridiza-
tion (FISH) [23,24], which has been widely used in the
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Variable PIK3CA mutations (n = 113) PIK3CA amplification (n = 131)
Yes No P Yes No P
No.of patients 8 105 88 43
Gender
Male 5 82 0.57 68 34 0.82
Female 3 23 20 9
Age, years
Mean 55.5 59.1 0.47 58.6 61.4 0.25
SD 19.8 12.7 13.3 12.1
Tumor localization
gastric cardia 0 26 0.98 23 12 0.66
gastric body 5 24 22 12
gastric antrum 3 55 43 19
Tumor size (cm
3)
≤ 3 3 35 0.68 29 14 0.88
3-5 3 35 32 15
>5 2 3 5 2 7 1 4
Differentiation
well/moderate 1 44 0.21 33 23 0.08
poor/undifferentiation 7 61 55 20
Tumor invasion
T1 2 14 0.96 9 5 0.59
T2 0 17 15 8
T3 6 72 62 30
T4 0 2 2 0
TNM stage
I 2 27 0.91 20 10 0.86
II 1 14 15 6
III 5 58 49 25
IV 0 6 4 2
Residual tumor
Yes 1 12 1.00 12 2 0.10
No 7 93 76 41
Lymph node metastasis (LNM)
Yes 5 65 1.00 57 24 0.32
No 3 40 31 19
No. of LNM
N0 3 40 0.63 31 19 0.20
N1 (1-6) 4 36 32 16
N2 (7-15) 1 23 20 7
N3 (≥ 16) 0 6 5 1
Survival status
Dead 3 53 0.73 51 15 0.01*
Alive 5 52 37 28
* Significant at P < 0.05
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TaqMan probes were designed using Primer Express 3.0
(Applied Biosystems) to amplify PIK3CA and b-actin
genes as described previously [18]. Using a PCR protocol
described previously [23], each sample was run in tripli-
cate, and b-actin was run in parallel to standardize the
input DNA. Standard curves were established using serial
dilutions of normal leukocyte DNA with a quantity range
of 3.75-60 ng per 2 μl. Copy gain (or amplification) of
PIK3CA gene was defined by a copy number ≥ 4.
Immunohistostaining (IHS) of phosphorylated akt (p-akt)
This procedure was pursued to investigate the level of p-
Akt in relation to PIK3CA copy gain in the tumor.
Briefly, formaldehyde fixed, paraffin-embedded tissue
sections (5 μm) were deparaffinized and rehydrated in
xylene and degradation alcohol. Antigen unmasking was
performed by pretreatment of the slides in 0.01 M citrate
buffer (pH 6.0) at 98°C for 15 min using a microwave
oven. The slides were then cooled to room temperature
on bench top for 20 min. Endogenous peroxidase was
cleaned by incubating the slides in 3% hydrogen peroxide
for 5 min. After washed in 0.01 M PBS (pH 7.4), the sec-
tions were incubated for 10 min at room temperature
with normal goat serum, followed by incubation with
anti-p-Akt antibody (BS4007, Bioworld Technology, Inc.,
MN) overnight at 4°C. The sections were subsequently
washed with PBS and incubated with biotinylated goat
anti-rabbit IgG (SP9000, Zhongshan Goldenbridge, Beij-
ing) and streptavidin-peroxidase complex, followed by
reaction with diaminobenzidine and counterstaining with
hematoxylin. Negative control was performed by omis-
sion of primary antibody. For positive control, we used
samples from previously examined gastric cancer tissues
positive for p-Akt. The level of p-Akt was scored in dou-
ble-blinding way (i.e., without knowing the PIK3CA copy
number of the case), and 0, 1, 2, 3 reprints negative, weak
positive, positive, and strong positive, respectively.
Statistical analysis
The Mann-Whitney U test was used to compare copy
number of PIK3CA gene between gastric cancer and
normal gastric samples. Correlation between PIK3CA
mutations or amplification and clinicopathological char-
acteristics was analyzed by Fisher’s exact test or Pear-
son’s Chi square test. The Mann-Whitney U test was
used for ordinal variables. Factors (PIK3CA mutations
or amplification) associated with clinicopathological
characteristics of tumor were assessed univariately using
the SPSS statistical package (11.5, Chicago, IL, USA).
Multivariate models were then developed that adjusted
for the most important covariates, including tumor size,
differentiation, tumor stage, lymph node metastasis and
survival status. Survival length was determined from the
day of primary tumor surgery to the day of death or last
clinical follow-up. The Kaplan-Meier method was used
for survival analysis grouping with PIK3CA mutations or
amplification. Differences between curves were analyzed
using the log-rank test. Multivariate Cox regression
analysis was used to evaluate the effect of PIK3CA
amplification on survival of independently of age, differ-
entiation, lymph node metastasis, and TNM stage. All
statistical analyses were performed using the SPSS statis-
tical package (11.5, Chicago, IL, USA). P values < 0.05
were considered significant.
Results
PIK3CA mutations and amplification in gastric cancer
As the first step to understand the role of PIK3CA gene in
gastric cancer, we sequenced exons 9 and 20 of this gene
in a large cohort of gastric cancers. A total of 8 PIK3CA
mutations (7.1%) were found in the 113 gastric cancers. Of
these, 3 mutations, including P539S, E542K and E545K,
were in the exon 9, and 5 mutations, including H1048D,
G1050S,W1057R,W1057C and I1062T, were in the exon
20. All mutations found were heterozygous missense sin-
gle base substitutions (see Additional file 1: Figure S1). To
analyze copy number of PIK3CA gene, real-time quantita-
tive PCR assay was performed in the 131 gastric cancers
and 37 normal controls. With a gene copy number of 4 or
more defined as amplification, we found the incidence of
PIK3CA amplification in gastric cancers was 67% (88/131)
in the present study, whereas no PIK3CA amplification
was found in the 37 normal controls. Copy number of
PIK3CA gene corresponding to each individual case of
gastric cancers and normal gastric tissues is shown in
Figure 1. Statistical analysis showed that copy number of
PIK3CA gene in gastric cancers was significantly higher
than normal gastric tissues (P < 0.0001).
To investigate the effect of PIK3CA amplification on the
activity of PI3K/Akt signaling pathway, we randomly
selected 13 gastric cancer samples with various PIK3CA
copies and did immunohistostaining for p-Akt. As illu-
strated by the representative samples in Figure 2A, and
all of selected 13 samples in Figure 2B, increased stain-
ing of p-Akt was seen with increased PIK3CA copies.
Association of PIK3CA mutations and amplification with
clinicopathological characteristics of gastric cancer
Because PIK3CA mutations and amplification, particu-
larly highly frequent PIK3CA amplification, was demon-
strated in gastric cancer, the association of PIK3CA
mutations and amplification with clinicopathological
characteristics was analyzed in a large cohort of clinically
well-characterized gastric cancers. As shown in Table 1,
PIK3CA mutations and amplification, particularly the for-
mer, showed no relation to most of clinicopathological
characteristics. PIK3CA amplification was significantly
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Although no statistical significance was noted, there was
a positive association of PIK3CA mutations and amplifi-
cation with tumor differentiation (Table 1). Similarly, the
univariate analysis also showed PIK3CA amplification
was associated with a significantly increased risk of can-
cer-related death (OR = 2.57, 95% CI = 1.21-5.48; P <
0.05), and there was a positive association of PIK3CA
mutations (OR = 5.05, 95% CI = 0.60-42.5) and PIK3CA
amplification (OR = 1.92, 95% CI = 0.92-4.01) with
tumor differentiation (see Additional file 1: Table S1). In
order to assess the independent association of PIK3CA
mutations and amplification with tumor size, tumor dif-
ferentiation, tumor stage, lymph node metastasis and sur-
vival status, we conducted two multivariable logistic
regressions (Table 2). Similar to univariate analysis, after
adjustment, PIK3CA amplification was still significantly
associated with higher mortality (OR = 3.50, 95% CI =
1.36-9.00; P <0 . 0 5 ) ,a n dPIK3CA mutations remained
positively associated with tumor differentiation (OR =
5.53, 95% CI = 0.65-47.4) (Table 2).
Effect of PIK3CA mutations and amplification on poor
survival in gastric cancer
The Kaplan-Meier estimator of the survivorship function
was used to determine the effect of PIK3CA mutations
and amplification on the survival of gastric cancer
patients. The overall survival of gastric cancer patients
with and without PIK3CA mutations/amplification was
compared using the log-rank test. As shown in Addi-
tional file 1: Figure S2, PIK3CA mutations did not affect
the overall prognosis of gastric cancer patients (P =
0.44). However, the patients with PIK3CA amplification
had significantly shorter survival times than the patients
without PIK3CA amplification (516.0 months vs. 758.4
months on average; P = 0.008).
Many evidences showed that residual tumor after sur-
gery is an independent risk factor for gastric cancer
patients. In the present study, indeed, the patients with
residual tumor after surgery had significantly shorter sur-
vival times than the patients without residual tumor
(343.2 months vs. 627.6 months on average; P = 0.002)
(Figure 3). Thus, we excluded the patients with residual
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Figure 1 Copy number of the PIK3CA gene corresponding to each individual case of gastric cancers and normal gastric tissues (circle).
Real-time quantitative PCR was performed to analyze the copy number of PIK3CA gene in a large cohort of gastric cancers and normal gastric
tissues. Details are as described in Methods. Horizonal lines indicate a 95% confidence interval for the sample mean. T, tumor tissues; N, normal
gastric tissues.
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Figure 2 Immunohistostaining of phosphorylated Akt (p-Akt): correlation of PIK3CA copies with increased p-Akt level.( A)
Representative samples of immunohistostaining on gastric cancer histologic slides using anti-p-Akt antibodies. Increasing extent of specific
staining (brown color) in association with increasing PIK3CA copies (number inside brackets). (B) Association of immunohistostaining (IHS) score of
p-Akt with PIK3CA copies on 13 randomly selected gastric cancer samples.
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and amplification with the survival of gastric cancer
patients again. Similar to the findings in Additional file 1:
Figure S2, PIK3CA mutations did not have any prognos-
tic value for gastric cancer patients (Figure 4A). However,
PIK3CA amplification significantly affected clinical
outcomes of gastric cancer patients. The patients with
PIK3CA amplification had significantly shorter survival
times than the patients without PIK3CA amplification
(540.0 months vs. 794.4 months on average; P =0 . 0 3 )
(Figure 4B). The data were stratified further according to
the TNM tumor stage, because it is an independent risk
Table 2 PIK3CA mutations and amplification in gastric cancer–multivariable models assessing tumor size,
differentiation, tumor stage, lymph node metastasis and survival status (OR
† and 95%CI)
Factors PIK3CA mutations [OR
† (95% CI)] PIK3CA amplification [OR
† (95% CI)]
Tumor size
1 0.80 (0.29-2.21) 0.88 (0.50-1.54)
Differentiation
2 5.53 (0.65-47.4) 1.85 (0.86-4.02)
Tumor stage
3 1.19 (0.33-4.35) 0.60 (0.31-1.17)
Lymph node metastasis 1.32 (0.13-13.6) 1.44 (0.45-4.58)
Survival status
4 0.41 (0.07-2.41) 3.50 (1.36-9.00)*
* Significant at P < 0.05
† OR: odds ratio with 95% confidence interval
1 Tumor size (≤ 3 cm; > 3 cm and ≤ 5 cm; > 5)
2 Differentiation (well or moderate; poor or no differentiation)
3 Tumor stage (I; II; III; IV)
4 Survival status (alive; dead)
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Figure 3 Effect of residual tumor after surgery on poor survival in gastric cancer. Clinical outcome was evaluated according to the
presence of residual tumor after surgery in a number of gastric cancers. Kaplan-Meier survival curves show that the patients with residual tumor
after surgery had significantly shorter survival times than the patients without residual tumor (P = 0.01). +, the patients with residual tumor after
surgery; -, the patients without residual tumor after surgery.
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and 4D, PIK3CA amplification was significantly asso-
ciated with poor survival whatever the patients who had
early-stage tumors (stage I and II) or late-stage tumors
(stage III and IV). Multivariate Cox regression analysis
indicated that PIK3CA amplification is a predictor of
poor prognosis for gastric cancer patients (HR = 2.59,
95% CI = 1.39-4.82, P = 0.003) as an independently vari-
able with respect to age, differentiation, lymph node
metastasis, and TNM stage (Table 3).
Discussion
It has been well documented that the PI3K/Akt pathway
plays an important role in cancer-related functions of
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Figure 4 Association of PIK3CA mutations and amplification with clinical outcome in patients with gastric cancer. Kaplan-Meier analysis
of survival was performed according to the presence of PIK3CA mutations or amplification in a large cohort of gastric cancers. (A) Kaplan-Meier
survival curves show that PIK3CA mutations were not associated with poor survival of the patients. (B) The patients with PIK3CA amplification had
poorer survival than the patients without PIK3CA amplification. (C) PIK3CA amplification was extremely significantly associated with poor survival
in the patients who had early-stage tumors (P = 0.004). (D) PIK3CA amplification was marginally significantly associated with poor survival in the
patients who had late-stage tumors (P = 0.06). PIK3CA Mu, PIK3CA mutations; PIK3CA Am, PIK3CA amplification; +, harboring PIK3CA mutations or
amplification; -, the lack of PIK3CA mutations or amplification.
Table 3 Multivariate Cox regression analysis of clinical
variables on overall survival
Variable HR
† 95% CI P
PIK3CA amplification 2.59 1.39-4.82 0.003
Age
1 1.28 0.98-1.67 0.07
Differentiation
2 1.16 0.66-2.05 0.61
Lymph node metastasis
3 2.70 1.01-7.21 0.047
TNM stage
4 2.07 1.17-3.65 0.01
† HR: Hazard Ratio
1 Age (per 10 years)
2 Differentiation (well or moderate; poor or no differentiation)
3 Lymph node metastasis (Yes vs. No)
4 Tumor stage (I; II; III; IV)
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[10,16,17,26,27], and it has a crucial role in the tumori-
genesis and pathogenesis of many human cancers. The
previous studies have shown that PIK3CA,a sas u b u n i t
of PI3K, is frequently mutated in various human can-
cers, such as ovarian, thyroid cancer, breast, cervical
cancers, and pituitary tumors [10,12,13,16,17,21,28].
However, our study showed that the most common acti-
vating PIK3CA mutations reported in other cancers
were not frequent in gastric cancer. Therefore, the
PIK3CA mutations may not be a common mechnaism
in the activation of PI3K/Akt signaling pathway. Instead,
our study demonstrated PIK3CA gene was highly ampli-
fied in gastric cancer. Genomic amplification, rather
than gene mutations, may represent another major sig-
nature of neoplastic transformation and tumor progres-
sion [29]. Chromosome copy number abnormalities
have been frequently identified in gastric cancer [30],
including PIK3CA amplification [31].
Of particular interest was the PIK3CA amlification was
closely associated with elevated p-Akt, suggesting that
this genetic alteration could lead to oncogenic activation
of PI3K/Akt signaling pathway and thus contributed to
the malignant progression of gastric cancer. It was con-
sistent with a previous study [31], which PIK3AC gene
was aberrantly amplified, and mutually excluded with
monallelic deletion of PTEN gene in gastric cancer,
further supporting that PIK3CA amplification, like
PTEN loss, might contribute to gastric tumorigenesis
through the activation of the PI3K/Akt pathway.
Given PIK3CA mutations and amplification play the
critical role in gastric tumorigenesis, we investigated
their clinical significances and prognostic values in a
large cohort of gastric cancer patients who had known
survival data. Out data showed that PIK3CA mutations
were not associated with most of clinicopathological
characteristics and clinical outcome in gastric cancer.
O n ep o s s i b i l i t yi st h el i m i t e dn u m b e ro fPIK3CA muta-
tions found in this study. However, PIK3CA amplifica-
tion was associated with a significantly increased risk of
cancer-related death, and positively associated tumor
differentiation. Most noteworthy, PIK3CA amplification
significantly affected the overall prognosis in gastric can-
cer whatever the patients who had early-stage or late-
stage tumors, suggesting that this genetic event plays an
important role in the multistep process of gastric carci-
nogenesis. Taken together, PIK3CA amplification may
be served as a potential prognostic marker for gastric
cancer patients.
The prognostic markers may have another role in pre-
dicting and guiding the clinical treatment of cancer
patients by allowing the identification of patients suited
to current therapies. In this era of molecularly targeted
therapy, inhibitors and antibodies targeting specific
molecules are vigorously being developed, and some
have been demonstrated to be effective in clinical set-
tings, such as hematological malignancies [32] and non-
small cell lung cancer (NSCLC) [33,34]. Of interest,
some of these targeted drugs are more effective against
the genetically altered cancerous form of the target, as
illustrated by the activities of gefitinib and erlotinib
against the mutated EGFR present in NSCLC [33,34],
and the activity of trastuzumab against breast cancer
with amplified ErbB2 [35]. Mutations and amplification
of certain kinases are involved in gastric tumorigenesis.
However, only has trastuzumab, which is a monoclonal
antibody targeting ErbB2, been recently approved as the
first molecularly targetd drug against gastric cancer. The
PI3K/Akt pathway is one of the most important signal-
ing pathways in human carcinogenesis. In the present
s t u d y ,ah i g hp r e v a l e n c eo fPIK3CA amplification was
found in gastric cancer, which was significantly asso-
ciated with poor prognosis of gastric cancer patients.
Importantly, PIK3CA amplification could aberrantly acti-
vate the PI3K/Akt signaling pathway. In addition, the
drugs, such as mTOR and Akt inhibitors that target this
signaling pathway, are being vigorously developed [36].
Thus, for some gastric cancer patients harbored onco-
genic alterations within the PI3K/Akt signaling pathway,
such as PIK3CA amplification, combination therapy
with an mTOR or Akt inhibitor should be considered.
Conclusions
In summary, our data showed that PIK3CA mutations
may not be frequent genetic event in gastric cancer,
however, PIK3CA gene was highly amplified in gastric
cancer. To our knowledge, the present study is the first
to demonstrate that PIK3CA amplification was signifi-
cantly associated with poor survival in gastric cancer.
More importantly, PIK3CA amplification was closely
associated with elevated p-Akt, suggesting that this
genetic alteration may be a major mechanism in activat-
ing the PI3K/Akt signaling pathway, and contribute to
gastric tumorigenesis. Thus, specific genotype-based tar-
geting against the PI3K/Akt signaling pathway may be
an effective therapeutic strategy for gastric cancer.
Additional material
Additional file 1: Figure S1. Somatic mutations identified in the PIK3CA
gene in gastric cancers. Examples of somatic mutations found in the
helical and kinase domains of PIK3CA. Arrows indicate the position of the
missense mutations. The amino acid changes are given above the
arrows. Figure S2. Association of PIK3CA mutations and amplification
with poor survival in gastric cancer. Kaplan-Meier survival curves was
made according to the presence of PIK3CA mutations or amplification in
a large cohort of gastric cancers. (A) PIK3CA mutations were not
associated with poor survival of the patients. (B) The patients with
PIK3CA amplification had a significantly shorter survival than the patients
without PIK3CA amplification (P = 0.01). PIK3CA Mu, PIK3CA mutations;
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Page 9 of 11PIK3CA Am, PIK3CA amplification; +, harboring PIK3CA mutations or
amplification; -, the lack of PIK3CA mutations or amplification. Table S1.
PIK3CA mutations and amplification in gastric cancer–univariate
associations with clinicopathological features (OR† and 95%CI).
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